Alejandra B. Salinas

Alejandra B. Salinas

Auto-generated profile, based on publicly available information

Alejandra B. Salinas

Department of Medicine, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2018 in Tuberculosis
Verified
Journal Article
Open access
BRBlanca I Restrepo
Blanca I Restrepo
LKLéanie Kleynhans
Léanie Kleynhans
ASAlejandra B. Salinas
Alejandra B. Salinas
BABassent Abdelbary
Bassent Abdelbary
HTHappy Tshivhula
Happy Tshivhula
KRKatharina Ronacher
Katharina Ronacher
Type 2 diabetes (T2D) is a prevalent risk factor for tuberculosis (TB), but most studies on TB-T2D have focused on TB patients, been limited to one community, and shown a variable impact of T2D on TB risk or treatment outcomes. We conducted a cross-sectional assessment of sociodemographic and metabolic factors in adult TB contacts with T2D (versus no T2D), from the Texas-Mexico border to study Hispanics, and in Cape Town to study South African Coloured ethnicities. The prevalence of T2D was 30.2% in Texas-Mexico and 17.4% in South Africa, with new diagnosis in 34.4% and 43.9%, respectively. Contacts with T2D differed between ethnicities, with higher smoking, hormonal contraceptive use and cholesterol levels in South Africa, and higher obesity in Texas-Mexico (p < 0.05). PCA analysis revealed striking differences between ethnicities in the relationships between factors defining T2D and dyslipidemias. Our findings suggest that screening for new T2D in adult TB contacts is effective to identify new T2D patients at risk for TB. Furthermore, studies aimed at predicting individual TB risk in T2D patients, should take into account the heterogeneity in dyslipidemias that are likely to modify the estimates of TB risk or adverse treatment outcomes that are generally attributed to T2D alone.

16 December 2022 in Pathogens
Verified
Journal Article
Open access
PDF file
BRBlanca I Restrepo
Blanca I Restrepo
JSJulia M. Scordo
Julia M. Scordo
GAGénesis P. Aguillón-Durán
Génesis P. Aguillón-Durán
DADoris Ayala
Doris Ayala
AQAna Paulina Quirino-Cerrillo
Ana Paulina Quirino-Cerrillo
JTJoanne Turner
Joanne Turner
The elderly are understudied despite their high risk of tuberculosis (TB). We sought to identify factors underlying the lack of an association between TB and type 2 diabetes (T2D) in the elderly, but not adults. We conducted a case–control study in elderly (≥65 years old; ELD) vs. younger adults (young/middle-aged adults (18–44/45–64 years old; YA|MAA) stratified by TB and T2D, using a research study population (n = 1160) and TB surveillance data (n = 8783). In the research study population the adjusted odds ratio (AOR) of TB in T2D was highest in young adults (AOR 6.48) but waned with age becoming non-significant in the elderly. Findings were validated using TB surveillance data. T2D in the elderly (vs. T2D in younger individuals) was characterized by better glucose control (e.g., lower hyperglycemia or HbA1c), lower insulin resistance, more sulphonylureas use, and features of less inflammation (e.g., lower obesity, neutrophils, platelets, anti-inflammatory use). We posit that differences underlying glucose dysregulation and inflammation in elderly vs. younger adults with T2D, contribute to their differential association with TB. Studies in the elderly provide valuable insights into TB-T2D pathogenesis, e.g., here we identified insulin resistance as a novel candidate mechanism by which T2D may increase active TB risk.

1 September 2020 in American Journal of Infection Control
Verified
Journal Article
Closed access
SKSara Keller
Sara Keller
ASAlejandra Salinas
Alejandra Salinas
DWDeborah Williams
Deborah Williams
MMMary McGoldrick
Mary McGoldrick
LGLisa Gorski
Lisa Gorski
SCSara E. Cosgrove
Sara E. Cosgrove

20 April 2023 in Infection Control & Hospital Epidemiology
Verified
Journal Article
Open access
PDF file
SKSara C. Keller
Sara C. Keller
SHSusan M. Hannum
Susan M. Hannum
KWKimberly Weems
Kimberly Weems
OOOpeyemi Oladapo-Shittu
Opeyemi Oladapo-Shittu
ASAlejandra B. Salinas
Alejandra B. Salinas
TCthe Home Infusion CLABSI Prevention Collaborative
the Home Infusion CLABSI Prevention Collaborative
Objective: Central-line–associated bloodstream infection (CLABSI) surveillance in home infusion therapy is necessary to track efforts to reduce infections, but a standardized, validated, and feasible definition is lacking. We tested the validity of a home-infusion CLABSI surveillance definition and the feasibility and acceptability of its implementation.Design: Mixed-methods study including validation of CLABSI cases and semistructured interviews with staff applying these approaches.Setting: This study was conducted in 5 large home-infusion agencies in a CLABSI prevention collaborative across 14 states and the District of Columbia.Participants: Staff performing home-infusion CLABSI surveillance.Methods: From May 2021 to May 2022, agencies implemented a home-infusion CLABSI surveillance definition, using 3 approaches to secondary bloodstream infections (BSIs): National Healthcare Safety Program (NHSN) criteria, modified NHSN criteria (only applying the 4 most common NHSN-defined secondary BSIs), and all home-infusion–onset bacteremia (HiOB). Data on all positive blood cultures were sent to an infection preventionist for validation. Surveillance staff underwent semistructured interviews focused on their perceptions of the definition 1 and 3–4 months after implementation.Results: Interrater reliability scores overall ranged from κ = 0.65 for the modified NHSN criteria to κ = 0.68 for the NHSN criteria to κ = 0.72 for the HiOB criteria. For the NHSN criteria, the agency-determined rate was 0.21 per 1,000 central-line (CL) days, and the validator-determined rate was 0.20 per 1,000 CL days. Overall, implementing a standardized definition was thought to be a positive change that would be generalizable and feasible though time-consuming and labor intensive.Conclusions: The home-infusion CLABSI surveillance definition was valid and feasible to implement.

12 January 2023 in American Journal of Infection Control
Verified
Journal Article
Closed access
OOOpeyemi Oladapo-Shittu
Opeyemi Oladapo-Shittu
SHSusan M. Hannum
Susan M. Hannum
ASAlejandra B. Salinas
Alejandra B. Salinas
KWKimberly Weems
Kimberly Weems
JMJill Marsteller
Jill Marsteller
SKSara C. Keller
Sara C. Keller

14 March 2024 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
PDF file
OOOpeyemi Oladapo-Shittu
Opeyemi Oladapo-Shittu
SCSara E Cosgrove
Sara E Cosgrove
CRClare Rock
Clare Rock
YHYea-Jen Hsu
Yea-Jen Hsu
EKEili Klein
Eili Klein
SKSara C Keller
Sara C Keller
Background: There are no systematic measures of central line–associated bloodstream infections (CLABSIs) in patients maintaining central venous catheters (CVCs) outside acute care hospitals. To clarify the burden of CLABSIs in these patients, we characterized patients with CLABSI present on hospital admission (POA). Methods: Retrospective cross-sectional analysis of patients with CLABSI-POA in 3 health systems covering 11 hospitals across Maryland, Washington DC, and Missouri from November 2020 to October 2021. CLABSI-POA was defined using an adaptation of the acute care CLABSI definition. Patient demographics, clinical characteristics, and outcomes were collected via record review. Cox proportional hazard analysis was used to assess factors associated with the all-cause mortality rate within 30 days. Results: A total of 461 patients were identified as having CLABSI-POA. CVCs were most commonly maintained in home infusion therapy (32.8%) or oncology clinics (31.2%). Enterobacterales were the most common etiologic agent (29.2%). Recurrent CLABSIs occurred in a quarter of patients (25%). Eleven percent of patients died during the hospital admission. Among patients with CLABSI-POA, mortality risk increased with age (hazard ratio vs age <20 years by age group: 20–44 years, 11.2 [95% confidence interval, 1.46–86.22]; 45–64 years, 20.88 [2.84–153.58]; ≥65 years, 22.50 [2.98–169.93]) and lack of insurance (2.46 [1.08–5.59]), and it decreased with CVC removal (0.57 [.39–.84]). Conclusions: CLABSI-POA is associated with significant in-hospital mortality risk. Surveillance is required to understand the burden of CLABSI in the community to identify targets for CLABSI prevention initiatives outside acute care settings.